Ann: Client Outlook Acquisition and Capital Raise Presentation, page-30

Hi hingdog,

Does the market equate to brokers generating false hype? PME has been a stockbroker's worst nightmare, meanwhile M7T continues to be a dream come true.
I sold out of my PME holdings last year as it became too pricey, and have been considering M7T as an alternative. But I just can't see it.

PME ever only raised $2m of shareholder capital. M7T is almost at $50m and counting.
Since 2015, PME has grown revenues by 300% and profits by $20m (or ~650%). Meanwhile in the same time period, M7T, has grown revenue by 30% and losses have ballooned out further.
PME has only ever delivered on targets, meanwhile M7T was spruiked as on track to generate EBITDA/NPAT gains by FY2018 (but they're still losing, and losing by more every year).

It seems M7T's sales growth has come at the expense of margin, so is the company undercutting the market to deliver contract announcements?

Which brings us to the latest announcement, that of a major acquisition (albeit with a company that they've partnered with when tendering to hospitals, etc.). Is it to hide the poor financial performance of the company?